In a bid to revolutionize drug development, Salesforce’s research project, ProGen, aimed to leverage generative AI to design proteins efficiently.
Despite promising results published in a January 2023 Nature Biotech article, the project remained largely dormant until one of its researchers, Ali Madani, founded Profluent, a startup dedicated to commercializing protein-generating technology for pharmaceutical companies.
Madani, along with co-founder Alexander Meeske, seeks to redefine the drug development process by prioritizing patient needs and tailoring treatments accordingly. The core idea revolves around utilizing AI-designed proteins as personalized medicine, potentially offering groundbreaking solutions for various diseases.
The underlying technology involves training AI models on vast datasets containing over 40 billion protein sequences. By harnessing generative AI, Profluent aims to create and refine gene-editing systems to address genetic diseases effectively.
This approach represents a departure from traditional methods, which often involve functional tradeoffs and lengthy development timelines. Profluent secured $35m in funding on 21st March
The significance of AI in predicting proteins has been underscored by other notable endeavors. Companies like Nvidia, Meta, and DeepMind have demonstrated the efficacy of AI models in drug discovery and protein structure prediction. It’s strategy builds upon these advancements, aiming to expedite the drug development process and reduce associated costs.
Nvidia in 2022 released a generative AI model, MegaMolBART, that was trained on a data set of millions of molecules to search for potential drug targets and forecast chemical reactions.
Backed by prominent venture capital firms and Google chief scientist Jeff Dean, Profluent is poised to make a substantial impact in the biotech industry. With plans to enhance AI models and forge partnerships, the company is positioned for rapid growth. Despite competition from other players in the field, Profluent remains focused on its mission to revolutionize biology solutions through intentional design.
-
How does Profluent’s technology differ from traditional drug development methods?
Profluent’s approach utilizes generative AI to design proteins tailored to individual patient needs, offering a more personalized approach to medicine. Traditional methods often involve lengthy development timelines and functional tradeoffs.
-
What datasets does Profluent use to train its AI models?
Profluent trains its AI models on vast datasets containing over 40 billion protein sequences, enabling the creation of novel gene-editing systems and protein-producing technologies.
-
How does Profluent plan to collaborate with pharmaceutical companies?
Profluent aims to collaborate with pharmaceutical companies to develop “genetic medicines” with promising paths to regulatory approval. By leveraging its AI technology, Profluent seeks to expedite the drug development process and reduce associated costs.
-
What sets Profluent apart from other players in the field?
Profluent’s focus on intentional design and personalized medicine distinguishes it from other companies in the biotech industry. Backed by prominent investors and industry experts, Profluent is poised to revolutionize drug development through AI-designed proteins.